Industry analysis, market data, and educational perspectives on the U.S. life settlement market — for qualified investors and capital allocators.
The U.S. secondary life insurance market represents one of the largest and most structurally sound alternative asset opportunities available to institutional capital. Here's what the numbers show — and why the window for early positioning is narrowing.
A plain-language primer on how the secondary life insurance market works, who participates in it, and why institutional allocation is accelerating in 2026.
Non-correlation is a term that gets used loosely. Here's a precise look at what it means in the context of life settlement acquisitions and why it matters for portfolio construction.
Baby Boomer aging is not a trend — it's a decade-long structural shift creating sustained acquisition pipeline. Here's what the population data says about the market's trajectory.
How life expectancy estimates are derived, why independent underwriting matters, and how actuarial variance affects the return distribution across scenarios.
Long-duration, non-correlated exposure independent of public markets is increasingly sought after. Here's how family offices are thinking about life settlement acquisitions in 2026.
A high-level overview of the state regulatory landscape governing life settlement transactions in the U.S. — and how it affects acquisition strategy and compliance requirements.
LifeChain publishes institutional-grade market perspectives on the U.S. life settlement industry. New articles are added regularly. For direct investor communications, contact the team.